Evidence map›Paper›PMID 35884124›Full record

ArticleAntibiotics (Basel, Switzerland)2022

In Silico Docking, Resistance Modulation and Biofilm Gene Expression in Multidrug-Resistant

Neveen A Abdelaziz, Walid F Elkhatib, Mahmoud M Sherif, Mohammed A S Abourehab, Sara T Al-Rashood, Wagdy M Eldehna, Nada M Mostafa, Nooran S Elleboudy

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Cinnamic Acid Compounds (Antibiotics (Basel, Switzerland) · 2025
    Article
  4. Novel Coumarins Derivatives for A. baumannii Lung Infection Developed by High-Throughput Screening and Reinforcement Learning.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024
    Article
  5. Article
  6. Article
  7. Antibacterial and antibiofilm potentials ofSaudi journal of biological sciences · 2024
    Article
  8. The use of combination therapy for the improvement of colistin activity against bacterial biofilm.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Review
  9. Review
  10. Article
  11. Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Neveen A AbdelazizDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, Sixth of October City 12451, Egypt.ORCID 0000-0001-9799-5507
Walid F ElkhatibDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, African Union Organization St., Abbassia, Cairo 11566, Egypt.
Mahmoud M SherifDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, Sixth of October City 12451, Egypt.
Mohammed A S AbourehabDepartment of Pharmaceutics, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-1348-6567
Sara T Al-RashoodDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Wagdy M EldehnaDepartment of Chemistry, School of Biotechnology, Badr University in Cairo, Cairo 11829, Egypt.ORCID 0000-0001-6996-4017
Nada M MostafaDepartment of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.ORCID 0000-0003-1602-2725
Nooran S ElleboudyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, African Union Organization St., Abbassia, Cairo 11566, Egypt.ORCID 0000-0002-1643-5709

Funding

King Saud University, Riyadh, Saudi ‎Arabia; Deanship of Scientific Research at Umm Al-Qura University ‎ Researchers Supporting Project number (RSP-2021/103); Grant Code: (22UQU4290565DSR08)‎
6 · The paper itself

Abstract

Despite the mounting global burden of antimicrobial resistance (AMR), the generation of new classes of effective antimicrobials still lags far behind. The interplay between multidrug resistance and biofilm formation in Acinetobacter baumannii has drastically narrowed the available therapeutic choices. The use of natural compounds holds promise as an alternate option for restoring the activity of existing antibiotics and attenuating virulence traits through reduced biofilm formation. This study aimed to evaluate the modulatory effect of combining cinnamic and gallic acids at ½MIC with various antibiotics against multidrug-resistant (MDR) A. baumannii clinical isolates as well as study the effect on the expression of the biofilm-associated genes (bap, csuE, ompA) via quantitative, real-time PCR. Combining cinnamic or gallic acid with imipenem, amikacin or doxycycline resulted in significant reduction of resistance (p < 0.05). On the contrary, no effect was recorded when both acids were combined with levofloxacin, and only cinnamic acid had a synergistic effect with colistin. The transcriptomic changes of biofilm-related genes in the presence of gallic acid at ½MIC were compared with untreated control samples. The fold expression values proved that gallic acid substantially down-regulated the respective genes in all five strong biofilm formers. Molecular docking studies of gallic and cinnamic acids on target genes revealed good binding affinities and verified the proposed mechanism of action. To the best of our knowledge, this is the first report on the effect of gallic acid on the expression of bap, csuE and ompA genes in A. baumannii, which may permit its use as an adjunct anti-virulence therapeutic strategy.

Indexed as

Acinetobacter baumanniibiofilmcinnamic acidgallic acidresistance modulation

Identifiers

PMID35884124
PMCPMC9311515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.